Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akoya Biosciences Inc (NQ: AKYA )

9.030 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 9.030
Bid (Size) 8.000 (3)
Ask (Size) 17.40 (1)
Prev. Close 9.030
Today's Range 9.030 - 9.030
52wk Range 8.020 - 23.44
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Where Akoya Biosciences Stands With Analysts
Akoya Biosciences (NASDAQ:AKYA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Akoya Biosciences Earnings Preview
Akoya Biosciences (NASDAQ:AKYA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Akoya... 
Via Benzinga

Performance

YTD
-39.68%
-39.68%
1 Month
-19.66%
-19.66%
3 Month
-24.62%
-24.62%
6 Month
-32.76%
-32.76%
1 Year
-55.23%
-55.23%

More News

Read More
Earnings Scheduled For March 14, 2022
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Via Benzinga
Earnings Scheduled For August 10, 2021
Via Benzinga
52 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Via Benzinga
Exposures Product Safety
33 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Akoya Biosciences Inc (AKYA) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
50 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Via Benzinga
Exposures Product Safety
48 Biggest Movers From Friday
Via Benzinga
Akoya Biosciences Inc (AKYA) Q2 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Via Benzinga
Earnings Scheduled For May 18, 2021
Via Benzinga
64 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021
Via Benzinga
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Via Benzinga
Exposures COVID-19 Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.